All In Biotech

Drug Trial Radar · NCT07483385

Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation

Last checked: Nov 20, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

45

Planned (sponsor's estimate)

Start

Jan 13, 2026

Primary completion

Jan 28, 2027

Study completion Jan 28, 2028

Sponsor

Lead sponsor
The General Hospital of Western Theater CommandAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an investigator-initiated prospective, single-center, open-label clinical trial designed to evaluate the clinical efficacy and safety of Lusutrombopag in promoting platelet remodeling after allogeneic hematopoietic stem cell transplantation in patients with hematologic disorders.

Conditions

  • Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation
  • Hematologic Disorders

Interventions

  • LusutrombopagDrug

    Lusutrombopag at a starting dose of 3 mg once daily. Treatment will continue for 2 weeks until CR is achieved, or treatment is discontinued after 14 days of continuous therapy, or when the discontinuation criteria are met. After the trial period plus 14 days, patients will be observed to determine if continued medication or regimen changes are necessary.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Transplantation + 21-day platelet accumulation engraftment rate Description: Transplantation + 21-day platelet accumulation engraftment rateTime frame: 21 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The General Hospital of the People's Liberation Army

    Chengdu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.